IRIS
ROSSI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.732
AS - Asia 1.542
EU - Europa 800
SA - Sud America 401
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 6
Totale 4.528
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.661
SG - Singapore 687
IT - Italia 391
CN - Cina 367
BR - Brasile 320
VN - Vietnam 187
IN - India 178
SE - Svezia 100
DE - Germania 97
GB - Regno Unito 72
CA - Canada 51
AR - Argentina 35
FI - Finlandia 31
BD - Bangladesh 25
NL - Olanda 20
EC - Ecuador 19
HK - Hong Kong 19
EU - Europa 18
FR - Francia 18
JP - Giappone 16
MX - Messico 15
RU - Federazione Russa 15
ID - Indonesia 14
RO - Romania 13
UA - Ucraina 11
ES - Italia 10
ZA - Sudafrica 9
CL - Cile 7
IQ - Iraq 7
PK - Pakistan 7
PY - Paraguay 7
TW - Taiwan 7
AT - Austria 6
CZ - Repubblica Ceca 6
AU - Australia 5
CO - Colombia 5
IR - Iran 5
TR - Turchia 5
EG - Egitto 4
TN - Tunisia 4
VE - Venezuela 4
CH - Svizzera 3
DZ - Algeria 3
PL - Polonia 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
MA - Marocco 2
MY - Malesia 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BW - Botswana 1
CI - Costa d'Avorio 1
CY - Cipro 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
IE - Irlanda 1
IL - Israele 1
KE - Kenya 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SN - Senegal 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.528
Salva come PNG Salva come JPEG
Città #
Singapore 245
Chandler 230
Dallas 165
Santa Clara 132
Hefei 126
Bengaluru 123
Milan 113
Lawrence 106
Princeton 106
Ho Chi Minh City 77
Ashburn 71
Beijing 63
Munich 59
Wilmington 58
Chicago 53
London 48
Catanzaro 47
Des Moines 40
Hanoi 34
Ottawa 28
São Paulo 25
Los Angeles 23
Turku 23
Council Bluffs 22
New York 20
Hong Kong 19
Brooklyn 16
Guangzhou 13
Redwood City 13
Naples 12
Pune 12
Boardman 11
Rome 11
Shanghai 11
Da Nang 10
Redmond 10
Rio de Janeiro 10
San Francisco 10
The Dalles 10
Tokyo 10
Montreal 9
Columbus 8
Haiphong 8
Helsinki 8
Porto Alegre 8
Biên Hòa 7
Brasília 7
Charlotte 7
Can Tho 6
Cosenza 6
Guayaquil 6
Horia 6
Jiaxing 6
Leawood 6
Mountain View 6
San Jose 6
Timisoara 6
Ahmedabad 5
Atlanta 5
Augusta 5
Belo Horizonte 5
Kulgam 5
Manchester 5
Olomouc 5
Quito 5
Reggio Calabria 5
Salvador 5
San Nicola Manfredi 5
Asunción 4
Baghdad 4
Bari 4
Berlin 4
Birigui 4
Dhaka 4
Hanover 4
Jakarta 4
Mexico City 4
Norwalk 4
Paris 4
Phoenix 4
San Antonio 4
Settingiano 4
Stockholm 4
Taoyuan District 4
Thái Bình 4
Toronto 4
Utrecht 4
Zhengzhou 4
Alexandria 3
Andover 3
Ankara 3
Barcelona 3
Boston 3
Bắc Giang 3
Caruaru 3
Castrovillari 3
Cetraro 3
Chennai 3
Clifton 3
Contagem 3
Totale 2.502
Salva come PNG Salva come JPEG
Nome #
A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations 149
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 117
miR-22 suppresses DNA ligase III addiction in multiple myeloma 95
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 80
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 72
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 69
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 63
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 62
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 60
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 58
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 57
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 57
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 57
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 57
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 55
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 55
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 53
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 52
CD7+ acute leukemia switching from a lymphoid to a myeloid phenotype 52
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 52
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 52
Enlarging the clinical spectrum of chorea-acanthocytosis 50
Role of Nucleophosmin in embryionic development and tumorigenesis 50
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 50
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 50
Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. 48
Mir-221/222 are promising targets for innovative anticancer therapy 47
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 47
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. 47
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 47
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 47
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 45
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 44
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 44
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 43
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 43
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 43
The non-coding RNA landscape of plasma cell dyscrasias 43
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 43
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 43
Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: Insights fromthe EYESHOT study 42
Dendritic cells have the option to express IDO-mediated suppression or not 42
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 42
Mycosis fungoides and gastric t-cell lymphoma: A case report 42
Daunorubicina liposomiale in ematologia 40
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 40
Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and adaptive Immunity 40
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 40
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 39
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 39
Translational Studies on the Bone Marrow Microenvironment in Multiple Myeloma: Experimental Models and Emerging Therapeutical Strategies 39
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 38
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 38
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 38
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 38
Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia 37
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 37
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 36
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 36
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 36
null 36
Mouse models of Multiple Myeloma: technologic platforms and perspectives 35
Emerging Role of MicroRNAs in the Pathophysiology of Immune System 35
Immunologic microenvironment and personalized treatment in multiple myeloma 34
Multiple myeloma-related bone disease: state-of-art and future treatments 34
Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management? 34
Selective targeting of IRF4 by sytnthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 34
Molecular Targets for the Treatment of Multiple Myeloma 34
Multiple Myeloma Cells downregulatemiR-29b in dendritic cells to promote a tumor permissive inflammatory microenvironment and immune escape 33
Osteonecrosis of the Jaw Prevention and Management in Modern Oncology 33
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 32
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells 32
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 30
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress 30
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 29
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 29
Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia 29
Targeting miR-21 in bone marrow stromal cells restores RANKL/OPG ratio within multiple myeloma microenvironment 29
MicroRNAs in multiple myeloma and related bone disease 29
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 29
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 28
CFD analysis of different arterial cannulation site during Heart Surgery with Cardioplumnonary Bypass 28
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 27
Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients 27
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 27
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor 26
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 26
Non-Coding RNAs in multiple myeloma bone disease pathophysiology 26
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 26
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 26
Primary large B-cell lymphoma involving the cerebellopontine angle mimic acoustic schwannoma: Role of MR Spectroscopy in differential diagnosis. A case report 25
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 24
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 23
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 23
MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches 22
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma 21
Hedgehog pathway in myeloma pathobiology and as potential therapeutic target 21
New Approaches to Predict Outcome and Personalize Therapy in Multiple Myeloma: from microRNAs to Integrated Genomics 20
Pharmacological activation of the alternative estrogen receptor GPER triggers anti-tumor activity in multiple myeloma and Waldenström macroglobulinemia cells 20
Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor 20
Totale 4.203
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.501
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.501
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021177 0 0 0 0 23 12 7 20 36 35 39 5
2021/2022319 9 4 4 72 36 17 10 58 25 30 48 6
2022/2023723 223 37 33 46 69 54 4 49 103 38 51 16
2023/2024325 74 44 23 18 26 87 8 7 2 9 13 14
2024/20251.375 190 93 67 69 96 167 30 40 142 69 144 268
2025/20261.627 142 280 315 583 307 0 0 0 0 0 0 0
Totale 4.674